DBV Technologies SA · EURONEXT:DBV

DBV Technologies SA — Investor Presentation (August 2022)

39 slides from DBV Technologies SA's investor presentation, August 2022

  1. Slide 1: DBV Technologies August 2022

    ~O- dbv technologies August 2022

  2. Slide 2: Safe Harbor Statement

    SAFE HARBOR STATEMENT This presentation contains forward looking statements including, but not limited to, statements concerning the outcome or success of DBV’s clinical trials; its ability to successfully gain regulatory approvals and commercialize products; its ability to successfully advance its

  3. Slide 3: DBV is a global, clinical-stage biopharmaceutical company

    DBV IS A GLOBAL, CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY We are dedicated to improving the lives of patients with food allergies and other immunological diseases Our science-driven leadership team has deep regulatory and commercial experience We have a dedicated team of ~100 professionals, with loc

  4. Slide 4: EPIT aims to re-educate the immune system by inducing regulatory T cells

    EPICUTANEOUS IMMUNOTHERAPY (EPIT™) AIMS TO RE-EDUCATE THE IMMUNE SYSTEM BY INDUCING SPECIFIC REGULATORY T CELLS1-6 Regulatory T Cells act on the immune system to alter allergic response EPIT delivers allergen • Decrease in allergen-specific IgE to intact skin Antigen Presenting Cells capture allerge

  5. Slide 5: The Viaskin patch uses minimal amounts of antigen

    THE VIASKIN™ PATCH, OUR NOVEL APPROACH TO EPIT™, USES MINIMAL AMOUNTS OF ANTIGEN TO INDUCE AN IMMUNE RESPONSE1-4 The condensation chamber enables natural epidermal water loss to solubilize dry antigen deposited on the patch using an innovative electrospray technology Condensation chamber Solubilized

  6. Slide 6: Viaskin has multiple potential applications in food allergies and other conditions

    VIASKIN™ HAS MULTIPLE POTENTIAL APPLICATIONS IN FOOD ALLERGIES AND IN OTHER IMMUNOLOGICAL CONDITIONS Epicutaneous immunotherapy and Viaskin™ are under clinical investigation and have not been approved for marketing by any health or regulatory authority. 6

  7. Slide 7: Multiple unmet needs in the management of peanut allergy

    THERE ARE MULTIPLE UNMET NEEDS CONCERNING THE MANAGEMENT OF PEANUT ALLERGY More Children Are Living with Peanut Allergy Than Ever Before • 860K children ages 4–11 have peanut allergy in the US,1,2 ~480K in EU2 • ~80% will not outgrow their allergy3 For Many Families, Avoidance Is Not Enough • Accide

  8. Slide 8: Allergists, families and children want additional protection from accidental exposure

    ALLERGISTS, FAMILIES, AND CHILDREN WANT ADDITIONAL PROTECTION FROM ALLERGIC REACTIONS DUE TO ACCIDENTAL PEANUT EXPOSURE Caregivers and physicians are seeking a treatment that1,2: 1. Reduces the likelihood of an allergic reaction in case of accidental exposure 2. Has a low risk of a serious reaction

  9. Slide 9: Reactions are determined by eliciting dose versus exposure dose

    OCCURRENCE OF REACTIONS IS DETERMINED BY THE RELATIONSHIP BETWEEN ELICITING DOSE AND EXPOSURE DOSE Eliciting Dose Exposure Dose Reaction Prediction The amount of allergen that induces The amount of allergen accidentally An allergic reaction is predicted to occur when a unmistakable allergic symptoms

  10. Slide 10: Modeling data: increasing eliciting dose decreases reaction risk

    MODELING* DATA SUGGEST INCREASING A PATIENT’S ELICITING DOSE DECREASES THE RISK OF AN ALLERGIC REACTION1 Decrease in Reaction Risk Following Allergen Immunotherapy ED after allergen immunotherapy 1,000 mg ED after allergen 300 mg 300 mg immunotherapy ED before allergen immunotherapy 100 mg 30 mg ED

  11. Slide 11: Viaskin Peanut clinical program

    VIASKIN™ PEANUT CLINICAL PROGRAM: COMMITTED TO GENERATING LONG-TERM DATA TO INFORM REAL-LIFE USE1 Phase 1 Phase 2b Phase 3 PEP01.09 VIPES 6-50 years of age 6-55 years of age 4-11 years of age 4-11 years of age 1-3 years of age 100 patients 221 patients 356 patients 393 patients 414 patients 2-week t

  12. Slide 12: Efficacy data of Viaskin Peanut in children ages 4-11

    EFFICACY DATA OF VIASKIN™ PEANUT IN CHILDREN AGES 4–11 YEARS Pivotal Phase 3 Study (PEPITES)1 Open-label Follow-on Study (PEOPLE)2 After 12 months, a 51.8% of subjects reached an ED of ≥1,000 mg at significantly larger Month 36, compared to 40.4% at Month 12 percentage of participants responded to V

  13. Slide 13: Viaskin Peanut safety information from clinical trials to date

    VIASKIN™ PEANUT SAFETY INFORMATION FROM CLINICAL TRIALS TO DATE1,2 Most Common AEs Treatment-related Anaphylaxis* and  In PEPITES (Months 0–12) and PEOPLE (Months 12–36), Epinephrine Use the most commonly reported treatment-related AEs  8 (3.4%) Viaskin™ Peanut participants were local application

  14. Slide 14: Modified Viaskin Peanut clinical and regulatory status

    MODIFIED VIASKIN™ PEANUT CLINICAL AND REGULATORY STATUS • We will conduct a pivotal Phase 3 trial, with an efficacy assessment, for mVP 1 • VITESSE (Viaskin Peanut Immunotherapy Trial to Evaluate Safety, Simplicity and Efficacy) • Continued engagement with FDA on key elements of the VITESSE protocol

  15. Slide 15: Topline Results

    TOPLINE RESULTS EPITOPE = (EPIT in TOddlers with PEanut Allergy) Epicutaneous immunotherapy and Viaskin™ are under clinical investigation and have not been 15 approved for marketing by any health or regulatory authority.

  16. Slide 16: Study Design

    STUDY DESIGN Part B* Viaskin Peanut Pivotal Global Phase 3 Trial 250 µg Randomized, double-blind, placebo-controlled • 362 patients aged 1-3 years • Randomized 2:1 Placebo • ~50 sites in US, Canada, Europe, Australia M0 M12 DBPCFC DBPCFC Primary endpoint: difference between the percentage of treatme

  17. Slide 17: Baseline Characteristics

    BASELINE CHARACTERISTICS VP250 Placebo Total (N=244) (N=118) (N=362) Age 1 year old 83 (34.0%) 43 (36.4%) 126 (34.8%) 2 years old 76 (31.1%) 38 (32.2%) 114 (31.5%) 3 years old 85 (34.8%) 37 (31.4%) 122 (33.7%) Eliciting Dose 100.0 100.0 100.0 Median (Q1, Q3) (30.00 ; 300.0) (30.00 ; 300.0) (30.00 ;

  18. Slide 18: Primary Endpoint

    PRIMARY ENDPOINT 80% P<0.001 70% Percent of Responders (%) 60% 67.0% 50% Δ= 33.4% 95% CI lower bound of 22.4% ≥ 15% → (95% CI: 22.4, 44.5) Primary endpoint is met, the study is positive 40% 30% 33.5% 20% 10% 0% VP250 Placebo (N=244) (N=118) CI=confidence interval; ED=eliciting dose; ITT=intent to tr

  19. Slide 19: Eliciting Dose ≥1,000 mg at Month 12

    ELICITING DOSE ≥1,000 mg AT MONTH 12 80% 70% P<0.001 Percent of Responders (%) 60% 64.2% 50% Δ= 34.7% (95% CI: 23.6, 45.7) 40% 30% 29.6% 20% 10% 0% VP250 Placebo (N=244) (N=118) CI=confidence interval; ED=eliciting dose; ITT=intent to treat population; VP250=Viaskin Peanut 250 µg. Treatment responde

  20. Slide 20: Safety Summary

    SAFETY SUMMARY Serious Adverse Events (VP250 vs placebo): 8.6% vs 2.5% Serious Adverse Events related to IMP (VP250 vs placebo): 0.4% vs 0% – Mild periorbital edema Adverse Events leading to study discontinuation (VP250 vs placebo): 3.3% vs 0% Anaphylactic reaction related to IMP (VP250 vs placebo):

  21. Slide 21: Summary

    SUMMARY Viaskin Peanut 250 µg resulted in a robust treatment effect in 1-3-year-olds with peanut allergy – 67% response rate vs. 33.5% for placebo (p<0.001); 95% CI lower bound 22.4% – 33.5% placebo response rate is consistent with an approximately 22% natural resolution rate for this age range1 and

  22. Slide 22: Viaskin Peanut may offer a convenient, easy-to-use treatment

    IF APPROVED, VIASKIN™ PEANUT MAY OFFER A CONVENIENT, EASY-TO-USE TREATMENT FOR PATIENTS AND THEIR FAMILIES Viaskin™ Peanut is designed to have the following features:  Applied at home, once a day  No treatment escalation, minimizing number of extra doctor's appointments  No activity limitations 

  23. Slide 23: 1H 2022 Financial Results

    1H 2022 FINANCIAL RESULTS  $248.0M in cash and cash equivalents as of June 30, 2022 – $14.1M1 raised through ATM in May – $181.2M1 raised in PIPE in June – $27.1M reimbursement of the French Research Tax Credit2  Cash used in operations decreased by 42%3 in 1H 2022 vs. 1H 2021  Cash runway expect

  24. Slide 24: DBV Contacts

    DBV CONTACTS Investor Relations Partnering and Licensing Anne Pollak general.inquiries@dbv-technologies.com +1 857-529-2363 anne.pollak@dbv-technologies.com Clinical Trial Participation clinicaltrials@dbv-technologies.com Public Relations and Media Angela Marcucci Medical Information +1 646-842-2393

  25. Slide 25: Appendix: Clinical Trial Data for Viaskin Peanut

    APPENDIX: CLINICAL TRIAL DATA FOR VIASKIN PEANUT

  26. Slide 26: Key Publications

    KEY PUBLICATIONS  Dioszeghy V, Mondoulet L, Dhelft V, et al. Epicutaneous immunotherapy results in rapid allergen uptake by dendritic cells through intact skin and downregulates the allergen-specific response in sensitized mice. J Immunol. 2011;186(10):5629-5637.  Mondoulet L, Dioszeghy V, Puteaux

  27. Slide 27: PEPITES and its 5-year open-label extension PEOPLE

    PEPITES AND ITS 5-YEAR, OPEN-LABEL EXTENSION, PEOPLE, IS THE LONGEST-TERM PEANUT IMMUNOTHERAPY TRIAL PEPITES (Viaskin™ Peanut 250 µg vs Placebo)1 PEOPLE (Viaskin™ Peanut 250 µg)2 M12 M24 M36 M38 M48 M60 Rollover to VP 250 µg 356 patients Placebo (n=118) n=107 n=100 91 83 • 4–11 years old • Confirmed

  28. Slide 28: Viaskin Peanut treatment effect after 12 months

    VIASKIN™ PEANUT TREATMENT EFFECT AFTER 12 MONTHS1 Change in Eliciting Dose Response Rate After 12 Months* After 12 Months† 40% P<0.001 100% 28.0% ED Increase 35.3% 80% 30% ED Stable Percent of Subjects Δ= 21.7% 62.6% ED Decrease (95% CI: 12.4, 29.8) 60% 20% 38.1% 40% 10% 13.6% 20% 30.7% 33.9% 0% 0%

  29. Slide 29: Change in cumulative reactive dose and eliciting dose with long-term treatment

    CHANGE IN CUMULATIVE REACTIVE DOSE (CRD) AND ELICITING DOSE WITH LONG-TERM VIASKIN™ PEANUT TREATMENT1 Cumulative Reactive Dose (mg) Mean, Median (-) PEOPLE Per Protocol (N=141) 3,000 2,500 75.9% of subjects demonstrated an increase in ED from baseline to Month 36 2,000 1768.8 1,500 51.8% of subjects

  30. Slide 30: Most commonly reported treatment-related adverse events

    MOST COMMONLY REPORTED TREATMENT-RELATED ADVERSE EVENTS PEPITES: Treatment-related TEAEs (occurring in ≥5% of subjects in 12 months)1 100% Placebo, n=118 Viaskin™ Peanut 250 µg, n=238 No treatment-related 80% gastrointestinal AEs observed % Subjects 59.7% 57.6% 60% 40% 34.7% 27.1% 20% 8.5% 5.5% 5.0%

  31. Slide 31: Change in frequency and severity of local administration site reactions

    CHANGE IN FREQUENCY AND SEVERITY OF LOCAL ADMINISTRATION SITE REACTIONS AFTER MONTH 1 Local Administration Site Reactions in the Viaskin™ Peanut 250 µg Group Over Time1* 100% Grade 4 Grade 3 Grade 2 Grade 1† In the extension study period between 83.4% 82.3% 12 and 36 months2: 76.9% 80% 72.6%  The m

  32. Slide 32: Rates of treatment-related anaphylaxis and epinephrine use

    RATES OF TREATMENT-RELATED ANAPHYLAXIS* AND EPINEPHRINE USE1,2  8 (3.4%) Viaskin™ Peanut participants experienced 10 Treatment-related TEAEs leading to events of treatment-related anaphylaxis* in 12 epinephrine use from M0–M12 months of treatment 10% – All were graded as mild or moderate without ev

  33. Slide 33: Treatment adherence and discontinuation rates

    TREATMENT ADHERENCE AND DISCONTINUATION RATES WITH VIASKIN™ PEANUT OBSERVED OVER 12, 36 MONTHS  98.5% treatment compliance at 12 months, comparable between Viaskin™ Peanut and placebo groups  A mean compliance of 98% was observed over 3 years of treatment  89.9% of all subjects completed the 12-m

  34. Slide 34: Clinical relevance of increasing eliciting dose

    CLINICAL RELEVANCE OF INCREASING A PATIENT’S ELICITING DOSE THROUGH ALLERGEN IMMUNOTHERAPY Decrease in risk of reaction as a function of increasing eliciting dose1 (example: ice cream)  A single peanut kernel contains ~250 to 300 mg of peanut protein2 Post-immunotherapy ED (mg peanut protein)  The

  35. Slide 35: Predicted risk reduction of reactions from peanut-contaminated foods

    PREDICTED RISK REDUCTION OF ALLERGIC REACTIONS CAUSED BY PEANUT-CONTAMINATED FOODS WITH VIASKIN™ PEANUT TREATMENT Modeling based on clinical trial data Risk reduction per Viaskin™ Peanut with Viaskin™ Peanut predicts: eating occasion1 250 µg Placebo  73%–78% reduction in the risk of an Cookies -77.

  36. Slide 36: Predicted risk reduction after 12 months of treatment

    PREDICTED RISK REDUCTION FOR ALLERGIC REACTIONS AFTER 12 MONTHS OF VIASKIN™ PEANUT TREATMENT1 Number needed to treat with Viaskin™ Peanut 250 µg 5.5 children for 12 months to prevent 1 allergic reaction 9.4 children Number needed to treat with Viaskin™ Peanut 250 µg for 12 months to prevent 1 modera

  37. Slide 37: Change in children's quality of life at 2 years

    CHANGE IN CHILDREN’S QUALITY OF LIFE WITH VIASKIN™ PEANUT OBSERVED AT 2 YEARS1 LS Mean Change from Baseline to Year 2 in FAQLQ Total Scores* Viaskin Peanut 250 µg during year 1 Placebo during year 1 FAQLQ Parent form (proxy)† FAQLQ Child form 0.4 N=89 0.2 0.08 0 -0.2 -0.4 -0.26 N=175 -0.39 -0.6 N=42

  38. Slide 38: Change in severity of allergic reactions with treatment

    CHANGE IN SEVERITY OF ALLERGIC REACTIONS WITH VIASKIN™ PEANUT TREATMENT1 Less severe symptoms with Viaskin™ Peanut 250 µg at the M12 DBPCFC1 Global score and score of organ systems most likely to indicate a life-threatening response Global Severity Score ⚫ Severe ⚫ Moderate ⚫ None or mild DBPCFC at

  39. Slide 39: Efficacy and safety in patients with concomitant allergic diseases

    EFFICACY AND SAFETY OF VIASKIN™ PEANUT IN PATIENTS WITH CONCOMITANT ALLERGIC DISEASES AT BASELINE Concomitant Atopic Dermatitis1 Concomitant Asthma2 Concomitant Food Allergies3 at Baseline at Baseline at Baseline ✓ Efficacy and safety results similar irrespective of ✓ Efficacy and safety results sim

DBV Technologies — Investor Presentation (August 2022) on 6ix